CAMBRIDGE, Mass., Sept. 3, 2015 /PRNewswire/ -- Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today announced that Jeffrey Albers, chief executive officer, will present a company overview at BioCentury's 22nd Annual NewsMakers in the Biotech Industry Conference on Thursday, September 10, 2015 at 3:00 p.m. EDT.

A live webcast of the event will be available by visiting the Investors section of the Blueprint Medicines website at www.blueprintmedicines.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.

About Blueprint Medicines

Blueprint Medicines makes kinase drugs to treat patients with genomically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer.

Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-the-22nd-annual-newsmakers-in-the-biotech-industry-conference-300135842.html

SOURCE Blueprint Medicines

Investor Relations: Hannah Deresiewicz, Stern Investor Relations, Inc., 212-362-1200, hannahd@sternir.com; Media Relations: Naomi Aoki, Ten Bridge Communications, Inc., 617-283-4298, naomi@tenbridgecommunications.com